Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment Strategies for Atopic Dermatitis, Psoriasis, and Alopecia Areata
Description
The talk reviewed practical treatment strategies for atopic dermatitis, psoriasis, and alopecia areata using case-based examples. For severe pediatric atopic dermatitis, the speaker argued that early biologic treatment, especially dupilumab, is often appropriate even in very young children because undertreatment can lead to infections, sleep loss, impaired growth, and developmental consequences; they also discussed how to handle live vaccines through coordination with pediatricians and dose timing. In pregnancy, dupilumab was presented as likely safe based on mechanistic reasoning and real-world data, with shared decision-making emphasized, and uncontrolled eczema was described as potentially harmful to both mother and fetus. For adolescents and adults with severe atopic dermatitis, JAK inhibitors were highlighted for rapid, high efficacy, while also addressing boxed warnings, baseline and follow-up lab monitoring, medication interactions, and counseling patients about actual versus theoretical risks; oral contraceptive use and smoking history were not shown to meaningfully change risk in available data. In psoriasis, IL-17 and IL-23 biologics were recommended as preferred options for patients with current or prior malignancy, with oncology collaboration depending on cancer timing and status. For alopecia areata, JAK inhibitors were presented as the main approved therapy, with baricitinib and ritlecitinib discussed; ritlecitinib was favored when weight gain and lipid changes emerged because it avoids JAK2-related metabolic effects and does not require lipid monitoring.
View moreConclusions
- Early use of dupilumab in severe pediatric atopic dermatitis may improve not only skin disease but also growth outcomes, supporting a lower threshold for systemic treatment when disease burden is high.
- Live vaccines, including MMR and varicella, appear to be usable in patients receiving dupilumab with shared decision-making and pediatric coordination, despite cautious labeling language.
- Uncontrolled atopic dermatitis in pregnancy is not benign, and treating maternal disease is likely safer than leaving inflammation unchecked because active disease may contribute to obstetric and neonatal complications.
- Dupilumab appears to be a reasonable and likely safe option during pregnancy, with the presentation emphasizing that first-trimester biologic exposure is theoretically lower risk and real-world data have not shown increased adverse pregnancy outcomes.
- For severe adolescent or young adult atopic dermatitis, JAK inhibitors are presented as the fastest and most effective short-term option, especially when rapid symptom control and oral convenience are priorities.
- The boxed-warning risks of JAK inhibitors in atopic dermatitis may be closer to background disease or population risk than to a true drug-related safety signal, based on the data shown.
- In routine practice, JAK inhibitors can be started safely with baseline labs, interaction checks, and ongoing monitoring, and abnormal counts or lipids can often be managed with recheck, dose adjustment, or coordinated treatment rather than automatic discontinuation.
- Oral contraceptive use or a history of smoking does not appear to meaningfully change the overall risk profile of upadacitinib in the presented atopic dermatitis data.
- For psoriasis patients with prior or active malignancy, IL-17 and IL-23 biologics are favored because available trial and real-world evidence does not show an obvious increase in cancer recurrence or progression.
- Management of psoriasis in the setting of malignancy should be individualized and coordinated with oncology rather than reflexively stopping all biologic therapy.
- For alopecia areata, JAK inhibition remains the key effective option, but treatment selection may be guided by longer-term safety concerns such as weight gain and lipid changes.
- Selective JAK3/TEC inhibition with ritlecitinib may be preferable when weight gain or lipid abnormalities emerge, since it avoids direct JAK2-mediated leptin and lipid effects.
- Zhang M et al. Medicine.
- Wan J et al. Journal of Allergy and Clinical Immunology: In Practice.
- Irvine, A, Paller, A, Siegfried, E, et al. Growth Analysis in Children Aged 6 to 11 Years and Adolescents Aged 12 to 17 Years with Moderate-To-Severe Atopic Dermatitis and Impact of 16 Weeks of Dupilumab Treatment on Height. Poster presentation, AAAAI 2025, San Diego, CA.#10.1016/j.jaci.2024.12.644
- Wechsler et al. J Allergy Clin Immunol Glob. 2021 Dec 8;1(1):9-15.
- Lieberman JA et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab. A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024 Sep;133(3):286-294.#10.1016/j.anai.2024.05.014
- Malek, A et al. Am. J. Reprod. Immunol. 1996, 36, 248–255.
- Bunick et al, MauiDerm 2024 Poster Presentation, Maui, HI; Daniele S, Bunick C. J Drugs Dermatol. 2022 Dec; 21(12):1298-1303.
- Stein Gold et al. EADV 2025.
- Issa et al. Fall Clinical 2025.
- Puig L. et al. Actas Dermo-Sifiliográficas, 2024.
- Bowe S, Murphy M, Bourke J, Ryan C. Clin Exp Dermatol. 2025 Aug 22;50(9):1818-1826.
- Zhang M et al. Medicine (Baltimore). 2023 Nov 24;102(47).
- Wan J et al. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2808-2810.
- Ibba L et al. Clin Exp Dermatol. 2025 Aug 22;50(9):1834-1837.